In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles (Q34819537)

4 August 2017

title

In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles (English)

1 reference

4 August 2017

0 references

Brian R Sloat

1

1 reference

4 August 2017

Michael A Sandoval

2

1 reference

4 August 2017

Dong Li

3

1 reference

4 August 2017

Woon-Gye Chung

4

1 reference

4 August 2017

Dharmika S P Lansakara-P

5

1 reference

4 August 2017

Philip J Proteau

6

1 reference

4 August 2017

Kaoru Kiguchi

7

1 reference

4 August 2017

John DiGiovanni

8

1 reference

4 August 2017

Zhengrong Cui

9

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 March 2011

1 reference

International Journal of Pharmaceutics

4 August 2017

published in

1 reference

4 August 2017

volume

409

1 reference

4 August 2017

issue

1-2

1 reference

4 August 2017

page(s)

278-288

1 reference

The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Tumor chemo-immunotherapy using gemcitabine and a synthetic dsRNA.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Magnetic poly epsilon-caprolactone nanoparticles containing Fe3O4 and gemcitabine enhance anti-tumor effect in pancreatic cancer xenograft mouse model.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Pancreatic cancer: from bench to 5-year survival

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Lecithin-based cationic nanoparticles as a potential DNA delivery system

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Novel targets for pancreatic cancer therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Selective Protection of 2',2'-Difluorodeoxycytidine (Gemcitabine).

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3079786

Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21371545

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Physiological parameters in laboratory animals and humans

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21371545

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.IJPHARM.2011.02.037

1 reference

4 August 2017

1 reference

4 August 2017

1 reference